Christopher G. Bunick, MD, PhD

Christopher Bunick, MD, PhD, discusses a novel tool to visualize key safety results of Janus kinase inhibitors in treating patients with atopic dermatitis.

Experts discuss the results of a study comparing the safety of Janus Kinase (JAK) inhibitors and systemic immunosuppressants in the treatment of atopic dermatitis (AD).

In the final part of this Frontline Forum series, James Del Rosso, DO; Hilary Baldwin, MD; Neal Bhatia, MD; Christopher Bunick, MD, PhD; and Leon Kircik, MD, discuss the use of clascoterone cream 1%, differences in isotretinoin formulations, targeting sebum production, acne guidelines for patient care, and more.

In part 3 of this Frontline Forum series, James Del Rosso, DO; Hilary Baldwin, MD; Neal Bhatia, MD; Christopher Bunick, MD, PhD; and Leon Kircik, MD, discuss the use of clascoterone cream 1%, differences in isotretinoin formulations, targeting sebum production, acne guidelines for patient care, and more.

Christopher Bunick, MD, PhD, introduces the objectives and design of a study comparing the safety of Janus Kinase (JAK) inhibitors and systemic immunosuppressants in the treatment of atopic dermatitis (AD).

Ruth Ann Vleugels, MD, MPD, MBA, provides important considerations for clinicians when reflecting upon the safety of oral Janus Kinase (JAK) inhibitors and traditional systemic immunosuppressants.

In part 2 of this Frontline Forum series, James Del Rosso, DO; Hilary Baldwin, MD; Neal Bhatia, MD; Christopher Bunick, MD, PhD; and Leon Kircik, MD, discuss the use of clascoterone cream 1%, differences in isotretinoin formulations, targeting sebum production, acne guidelines for patient care, and more.

In part 1 of this Frontline Forum series, James Del Rosso, DO; Hilary Baldwin, MD; Neal Bhatia, MD; Christopher Bunick, MD, PhD; and Leon Kircik, MD, discuss the pathogenesis of acne vulgaris, the use of clascoterone cream 1%, differences in isotretinoin formulations, targeting sebum production, acne guidelines for patient care, and more.

Christopher Bunick, MD, PhD, discusses the major study conclusions about the safety of upadacitinib as a treatment for atopic dermatitis.

Christopher Bunick, MD, PhD, presents the results of the long-term four-year safety study of upadacitinib as treatment for atopic dermatitis (AD).

Christopher Bunick, MD, PhD, introduces an integrated analysis of phase three studies analyzing the long-term safety of upadacitinib as treatment for atopic dermatitis (AD). He also highlights a burgeoning standard to assess the safety of treatment.

Ruth Ann Vleugels, MD, MPD, MBA, and Christopher Bunick, MD, PhD, provide their clinical experience with Janus Kinase (JAK) inhibitors and the importance of patient compliance with these agents.

Experts discuss a recent network meta-analysis comparing current monotherapies for atopic dermatitis (AD) and how this may change standards of care.

Christopher Bunick, MD, PhD, and Ruth Ann Vleugels, MD, MPD, MBA, discuss the method of action for Janus Kinase (JAK) inhibitors and the pathology of atopic dermatitis (AD).

Bunick presented 3 sessions at the 2023 World Congress of Dermatology meeting in Singapore.

Bunick spoke at the Fall Clinical Dermatology Conference for PAs and NPs to discuss important considerations of biologics use for atopic dermatitis management.

Aerosolized dry shampoo is the latest personal care product to contain detectable levels of benzene, according to Bunick’s SCALE 2023 session.

Christopher Bunick, MD, PhD, comments on the role isotretinoin plays in his practice and comments on further advancements in the management of this condition.

An expert in dermatology shares his opinion on oral versus topical acne treatment options and how to assess response to treatment.

Dr Christopher Bunick discusses the role the microbiome and sebum play in acne production and highlights the role Clascoterone cream 1% plays in targeting these agents.

Christopher Bunick, MD, PhD, provides an overview of acne vulgaris and the populations it impacts; highlighting that this is more than just an adolescent affliction and the role of sebum production.

Christopher Bunick, MD, PhD, shares pearls from his research in benzene contamination in sunscreens and what advice he shares with patients.

Bunick provides an overview of the most important highlights from his late-breaking session at RAD 2023.

Panelists share parting advice and key takeaways on the optimal management of atopic dermatitis within the treatment landscape.

Experts share insight on the challenges inherent in treating patients with atopic dermatitis despite recent advances in therapy.

Concluding their focused discussion on JAK inhibitors in atopic dermatitis, panelists share advice on the optimal selection based on route of administration and use of these agents.

A brief review of 2 oral JAK inhibitors recently approved for patients with atopic dermatitis.

A panel of experts review the use of topical ruxolitinib in atopic dermatitis, shedding light on safety and efficacy considerations.

Focusing on JAK inhibitors, panelists consider the historical use of these agents in atopic dermatitis and their corresponding mechanisms of action.

Experts define stages of atopic dermatitis and share insight on the conventional treatment landscape for mild to moderate and moderate to severe atopic dermatitis.